Meher Rizvi, Maria Khan, Amina Al-Jardani, Seif Salem Al-Abri, Ujjala Ghoshal, Zaaima Al Jabri, Mohammad Ahanjan, Azza Al Mamari, Nawal Al Shizawi, Hiba Sami, Abdullah Balkhair, Adila Shaukat, Alwarith Nasser Salem Alkharusi, Abdulrahman Almahrouqi, Afreenish Hassan, Ajay Kumar, Amal Saki Malehi, Amina Gul, Ashima Singh, Asma Said Hamed Al Shidhani, Areena Hoda Siddiqui, Aruna Poojary, Azza Al Rashdi, Bradley Langford, Dmytro Stepanskyi, Abbas Dolatabadi, Amal Al Maani, Aisha Al Mufarji, Elham Said Ahmed AlRisi, Garima Kapoor, Isabella Princess, Hawra J Al Lawati, Hatim Ali Eltahir, Hilal Al Sidairi, Katia Iskandar, Ken Masters, Ibrahim Khalaf Hamdan Al-Busaidi, Laila Al Yazidi, Mahfuza Nasrin, Mahmood Salim Al Subhi, Mallika Sengupta, Manisha Khandait, Nada Khalfan Al Tamtami, Nada Khafan Al Siyabi, Nawal Al Kindi, Nazla Musthafa Luthfee, Neha Shreshtha, Nihal Mohamed Amur Al Riyami, Noora Hilal Ali Al Busaidi, Nupur Goel, Oksana Ishchenko, Omnia Mohamed Elnabawy Ahmed Taher, Pragnya Paramita Jena, Rajni Ekadashi, Razan Al Zadjali, Reba Kanungo, Sara Abolghasemi, Salima Al Maqbali, Sayantan Banerjee, Shadma Yaqoob, Shahnaz Sali, Shafqat Husnain Khan, Shalini Malhotra, Stephen Hughes, Sundas Shaukat, Syed Mohammed Atif, Vrushali Vishwas Patwardhan, Victorien Dougnon, Wahid Khan, Walid Wali, Zakariya Al Muharrmi, Zeeshana Basit, Jasashree Choudhury, Rachita Pravalina, Keith H St John, Sanjeev Singh, Sarman Singh, Neelam Taneja, Raman Sardana, Abdul Ghafur, Pawan Kapoor, Rajeev Soman, Rashid Al Abri
{"title":"绘制低收入、中等收入和高收入国家社区获得性尿路致病性大肠杆菌的抗菌药物敏感性图，突出了显著差异：对经验性治疗的见解。","authors":"Meher Rizvi, Maria Khan, Amina Al-Jardani, Seif Salem Al-Abri, Ujjala Ghoshal, Zaaima Al Jabri, Mohammad Ahanjan, Azza Al Mamari, Nawal Al Shizawi, Hiba Sami, Abdullah Balkhair, Adila Shaukat, Alwarith Nasser Salem Alkharusi, Abdulrahman Almahrouqi, Afreenish Hassan, Ajay Kumar, Amal Saki Malehi, Amina Gul, Ashima Singh, Asma Said Hamed Al Shidhani, Areena Hoda Siddiqui, Aruna Poojary, Azza Al Rashdi, Bradley Langford, Dmytro Stepanskyi, Abbas Dolatabadi, Amal Al Maani, Aisha Al Mufarji, Elham Said Ahmed AlRisi, Garima Kapoor, Isabella Princess, Hawra J Al Lawati, Hatim Ali Eltahir, Hilal Al Sidairi, Katia Iskandar, Ken Masters, Ibrahim Khalaf Hamdan Al-Busaidi, Laila Al Yazidi, Mahfuza Nasrin, Mahmood Salim Al Subhi, Mallika Sengupta, Manisha Khandait, Nada Khalfan Al Tamtami, Nada Khafan Al Siyabi, Nawal Al Kindi, Nazla Musthafa Luthfee, Neha Shreshtha, Nihal Mohamed Amur Al Riyami, Noora Hilal Ali Al Busaidi, Nupur Goel, Oksana Ishchenko, Omnia Mohamed Elnabawy Ahmed Taher, Pragnya Paramita Jena, Rajni Ekadashi, Razan Al Zadjali, Reba Kanungo, Sara Abolghasemi, Salima Al Maqbali, Sayantan Banerjee, Shadma Yaqoob, Shahnaz Sali, Shafqat Husnain Khan, Shalini Malhotra, Stephen Hughes, Sundas Shaukat, Syed Mohammed Atif, Vrushali Vishwas Patwardhan, Victorien Dougnon, Wahid Khan, Walid Wali, Zakariya Al Muharrmi, Zeeshana Basit, Jasashree Choudhury, Rachita Pravalina, Keith H St John, Sanjeev Singh, Sarman Singh, Neelam Taneja, Raman Sardana, Abdul Ghafur, Pawan Kapoor, Rajeev Soman, Rashid Al Abri","doi":"10.1016/j.ijregi.2025.100706","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Rising antimicrobial resistance (AMR) in <i>Escherichia coli</i> urinary tract infections (UTI) poses a global challenge. Evidence-based treatment of cystitis requires local resistance data. The DASH to Protect Antibiotics (https://dashuti.com/), a multi-regional group, supports centers in generating and sharing focused antibiograms to guide stewardship in community UTIs. This multi-country study aimed to describe antimicrobial susceptibility patterns of community-acquired <i>E. coli</i> isolates in low, middle, and high-income countries (LMICs and HICs).</p><p><strong>Methods: </strong>The study was conducted in 37 representative centers across 13 countries in Asia (Middle East and Indian Subcontinent), Africa, Europe, and North America. A rigorous comparative analysis of the antimicrobial susceptibility of <i>E. coli</i> isolated from cases of simple cystitis presenting in outpatient or emergency departments was carried out. The impact of gross domestic product, climate, and population density per km<sup>2</sup> on <i>E. coli</i> susceptibility profile was analyzed using the Kruskal-Wallis test and two-way analysis of variance.</p><p><strong>Results: </strong>Antimicrobial susceptibility varied significantly between LMICs and HICs, with nitrofurantoin (89%) and fosfomycin (96%) emerging as empiric choices globally. Across most centers, susceptibility to other oral antimicrobials was low: co-trimoxazole <60%, amoxicillin-clavulanic acid <70%, first-generation cephalosporins <50%, fluoroquinolones <60%. Injectable antibiotics fared better: piperacillin-tazobactam >70%, amikacin and meropenem >80%. Higher susceptibilities were noted in countries with high gross domestic product (<i>P</i> < 0.001) and humidity (<i>P</i> = 0.002).</p><p><strong>Conclusion: </strong>Marked geographical differences in <i>E. coli</i> susceptibility patterns support the need for localized antibiograms and tailored empirical therapy. This study reinforces the utility of nitrofurantoin and fosfomycin as first-line agents and discourages the use of fluoroquinolones and third-generation cephalosporins.</p>","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"16 ","pages":"100706"},"PeriodicalIF":1.7000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357049/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mapping antimicrobial susceptibility of community-acquired uropathogenic Escherichia coli across low, middle and high-income countries highlights significant differences: insights for empiric treatment.\",\"authors\":\"Meher Rizvi, Maria Khan, Amina Al-Jardani, Seif Salem Al-Abri, Ujjala Ghoshal, Zaaima Al Jabri, Mohammad Ahanjan, Azza Al Mamari, Nawal Al Shizawi, Hiba Sami, Abdullah Balkhair, Adila Shaukat, Alwarith Nasser Salem Alkharusi, Abdulrahman Almahrouqi, Afreenish Hassan, Ajay Kumar, Amal Saki Malehi, Amina Gul, Ashima Singh, Asma Said Hamed Al Shidhani, Areena Hoda Siddiqui, Aruna Poojary, Azza Al Rashdi, Bradley Langford, Dmytro Stepanskyi, Abbas Dolatabadi, Amal Al Maani, Aisha Al Mufarji, Elham Said Ahmed AlRisi, Garima Kapoor, Isabella Princess, Hawra J Al Lawati, Hatim Ali Eltahir, Hilal Al Sidairi, Katia Iskandar, Ken Masters, Ibrahim Khalaf Hamdan Al-Busaidi, Laila Al Yazidi, Mahfuza Nasrin, Mahmood Salim Al Subhi, Mallika Sengupta, Manisha Khandait, Nada Khalfan Al Tamtami, Nada Khafan Al Siyabi, Nawal Al Kindi, Nazla Musthafa Luthfee, Neha Shreshtha, Nihal Mohamed Amur Al Riyami, Noora Hilal Ali Al Busaidi, Nupur Goel, Oksana Ishchenko, Omnia Mohamed Elnabawy Ahmed Taher, Pragnya Paramita Jena, Rajni Ekadashi, Razan Al Zadjali, Reba Kanungo, Sara Abolghasemi, Salima Al Maqbali, Sayantan Banerjee, Shadma Yaqoob, Shahnaz Sali, Shafqat Husnain Khan, Shalini Malhotra, Stephen Hughes, Sundas Shaukat, Syed Mohammed Atif, Vrushali Vishwas Patwardhan, Victorien Dougnon, Wahid Khan, Walid Wali, Zakariya Al Muharrmi, Zeeshana Basit, Jasashree Choudhury, Rachita Pravalina, Keith H St John, Sanjeev Singh, Sarman Singh, Neelam Taneja, Raman Sardana, Abdul Ghafur, Pawan Kapoor, Rajeev Soman, Rashid Al Abri\",\"doi\":\"10.1016/j.ijregi.2025.100706\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Rising antimicrobial resistance (AMR) in <i>Escherichia coli</i> urinary tract infections (UTI) poses a global challenge. Evidence-based treatment of cystitis requires local resistance data. The DASH to Protect Antibiotics (https://dashuti.com/), a multi-regional group, supports centers in generating and sharing focused antibiograms to guide stewardship in community UTIs. This multi-country study aimed to describe antimicrobial susceptibility patterns of community-acquired <i>E. coli</i> isolates in low, middle, and high-income countries (LMICs and HICs).</p><p><strong>Methods: </strong>The study was conducted in 37 representative centers across 13 countries in Asia (Middle East and Indian Subcontinent), Africa, Europe, and North America. A rigorous comparative analysis of the antimicrobial susceptibility of <i>E. coli</i> isolated from cases of simple cystitis presenting in outpatient or emergency departments was carried out. The impact of gross domestic product, climate, and population density per km<sup>2</sup> on <i>E. coli</i> susceptibility profile was analyzed using the Kruskal-Wallis test and two-way analysis of variance.</p><p><strong>Results: </strong>Antimicrobial susceptibility varied significantly between LMICs and HICs, with nitrofurantoin (89%) and fosfomycin (96%) emerging as empiric choices globally. Across most centers, susceptibility to other oral antimicrobials was low: co-trimoxazole <60%, amoxicillin-clavulanic acid <70%, first-generation cephalosporins <50%, fluoroquinolones <60%. Injectable antibiotics fared better: piperacillin-tazobactam >70%, amikacin and meropenem >80%. Higher susceptibilities were noted in countries with high gross domestic product (<i>P</i> < 0.001) and humidity (<i>P</i> = 0.002).</p><p><strong>Conclusion: </strong>Marked geographical differences in <i>E. coli</i> susceptibility patterns support the need for localized antibiograms and tailored empirical therapy. This study reinforces the utility of nitrofurantoin and fosfomycin as first-line agents and discourages the use of fluoroquinolones and third-generation cephalosporins.</p>\",\"PeriodicalId\":73335,\"journal\":{\"name\":\"IJID regions\",\"volume\":\"16 \",\"pages\":\"100706\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357049/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJID regions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijregi.2025.100706\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJID regions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ijregi.2025.100706","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Mapping antimicrobial susceptibility of community-acquired uropathogenic Escherichia coli across low, middle and high-income countries highlights significant differences: insights for empiric treatment.
Objectives: Rising antimicrobial resistance (AMR) in Escherichia coli urinary tract infections (UTI) poses a global challenge. Evidence-based treatment of cystitis requires local resistance data. The DASH to Protect Antibiotics (https://dashuti.com/), a multi-regional group, supports centers in generating and sharing focused antibiograms to guide stewardship in community UTIs. This multi-country study aimed to describe antimicrobial susceptibility patterns of community-acquired E. coli isolates in low, middle, and high-income countries (LMICs and HICs).
Methods: The study was conducted in 37 representative centers across 13 countries in Asia (Middle East and Indian Subcontinent), Africa, Europe, and North America. A rigorous comparative analysis of the antimicrobial susceptibility of E. coli isolated from cases of simple cystitis presenting in outpatient or emergency departments was carried out. The impact of gross domestic product, climate, and population density per km2 on E. coli susceptibility profile was analyzed using the Kruskal-Wallis test and two-way analysis of variance.
Results: Antimicrobial susceptibility varied significantly between LMICs and HICs, with nitrofurantoin (89%) and fosfomycin (96%) emerging as empiric choices globally. Across most centers, susceptibility to other oral antimicrobials was low: co-trimoxazole <60%, amoxicillin-clavulanic acid <70%, first-generation cephalosporins <50%, fluoroquinolones <60%. Injectable antibiotics fared better: piperacillin-tazobactam >70%, amikacin and meropenem >80%. Higher susceptibilities were noted in countries with high gross domestic product (P < 0.001) and humidity (P = 0.002).
Conclusion: Marked geographical differences in E. coli susceptibility patterns support the need for localized antibiograms and tailored empirical therapy. This study reinforces the utility of nitrofurantoin and fosfomycin as first-line agents and discourages the use of fluoroquinolones and third-generation cephalosporins.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
